本研究针对晚期前列腺癌(PCa)治疗需求，探索了免疫检查点分子B7-H3与酪氨酸激酶受体c-MET的共表达特征。湖北肿瘤医院团队通过135例FFPE样本的免疫组化分析发现，44%病例存在双阳性表达，但c-MET在癌旁组织表达更高。研究揭示了B7-H3作为PCa治疗靶点的潜力 ...

MSD and Daiichi Sankyo have announced first subject dosing in the randomised IDeate-Prostate01 Phase III trial of ifinatamab ...

Merck just kicked off its Phase 3 IDeate-Prostate01 trial, handing the first dose of ifinatamab deruxtecan to a patient ...

2025 年美国临床肿瘤学会 （ASCO 2025）年会于当地时间 5 月 30 日至 6 月 3 日在美国芝加哥举行。北京清辉联诺生物科技有限责任公司 （以下简称「清辉联诺」）宣布其提交的异体通用型 B7 H3 CAR-γδ T 细胞药物 QH104 用于治疗实体瘤软脑膜转移 （Leptomeningeal Metastasis, LM）的早期临床研究摘要，成功入选 ASCO 2025 ...

B7-H3, also known as CD276, is an immunoregulatory protein that is overexpressed in tumour tissue, notably in lung, breast, ovarian, gastric, and brain cancer, as well as squamous cell carcinoma ...

The first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) versus docetaxel in patients with metastatic ...

Merck and Daiichi Sankyo have announced that the first patient has been dosed in the IDeate-Prostate01 phase 3 trial ...

总体来看，明慧医药正在加速将科研价值转化为商业价值，通过战略BD交易实现研发与资本的良性循环。这一切都得益于公司以差异化研发战略构建的多维创新引擎，从而形成了长短结合的创新产品矩阵。

GSK has turned to China’s Hansoh Pharma to add another antibody-drug conjugate (ADC) to its oncology pipeline, this time licensing a B7-H3-targeting candidate for $185 million upfront.